Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022
August 02, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
July 31, 2022 10:00 ET
|
Anavex Life Sciences Corp.
Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer’s and Parkinson’s disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p<0.005) ...
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
June 21, 2022 08:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex’s Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome
June 08, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
May 19, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
May 10, 2022 07:00 ET
|
Anavex Life Sciences Corp.
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
May 03, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
April 27, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
April 26, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference
April 07, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...